Genetics of SARS-CoV-2

The genetics of SARS-CoV-2 has been controversial due to the debates over gain-of-function research and the origins story of the virus that led to COVID-19 pandemic policies.

Genetic RNA Structure

Codons

Early analysis of the genetics of SARS-CoV-2 which included examination of relative synonymous codon usage (RSCU) showed greatest similarity of genetic information with bat CoVs, but had most similar codon bias usage with snakes.1)

  • Analysis of SARS-CoV-2 synonymous codon usage evolution throughout the COVID-19 pandemic2)

HIV Components

* Oct 29, 1993 *

Philos Trans R Soc Lond B Biol Sci. 1993 Oct 29;342(1299):59-66. doi: 10.1098/rstb.1993.0136.

The role of CD4 in HIV binding and entry Q J Sattentau 1 , J P Moore 1 - Centre d'Immunologie de Marseille-Luminy, Marseille, France. PMID: 7904348 DOI: 10.1098/rstb.1993.0136

Abstract - The primary cellular receptor for the human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV is the CD4 antigen (Sattentau et al. 1988; Sattentau & Weiss 1988).

HIV infection of CD4+ cells is initiated by binding of the virus to the cell surface, via a high-affinity interaction between the first domain of CD4 and the HIV outer envelope glycoprotein, gp120. The use of a soluble recombinant form of CD4 (sCD4) as a receptor mimic has simplified the analysis of receptor binding and post-binding events which result in virus-cell membrane fusion.

With cell-line adapted isolates of HIV-1, sCD4 binding induces conformational changes in gp120, leading to the complete dissociation of gp120 from the transmembrane glycoprotein, gp41, and exposing cryptic epitopes of gp41. Similar observations have been made with cell-anchored CD4: recruitment of CD4 molecules leads to exposure of cryptic gp41 epitopes at the fusion interface between clusters of CD4 expressing and HIV-infected cells.

It has therefore been proposed that CD4 binding induces exposure of fusogenic components of gp41 which mediate virus-cell membrane coalescence, a process termed receptor-mediated activation of fusion. With the related lentiviruses HIV-2 and SIV, the CD4 induced molecular rearrangements in gp120 are more subtle, implying that there is a spectrum of responses to sCD4 binding. 3)

Incredible Discoveries - Rixey's homologous elements between HlV/SARS-CoV-2

Charles Rixey, MA MBA @CharlesRixey

How interesting. The parts of the env trimer for HlV found in the SARS-CoV-2 genome happen to match the epitopes targeted for vx studies since ~2015. They target the CD4 binding site. & DC-SIGN [CD209]. This is what was blocked by Fαuci in Jan 2020 @GigaohmResist @TyCardon

Fauci knew what these meant, because his VRC had been working on such candidates since at least 2006. He knew that Furin triggers cancer cell growth, and that HlV is enhanced by/enhances amyloid dev. The cascade of both would look just like what has shown us

This is what has become clear to me after reading 400 studies just looking at the homologous elements between HlV/SARS-CoV-2. It's the end result of the findings laid out in It's what they must hide until after the election 4)

Gain-of-Function

Specific Sequences

TATCAGACTCAGACTAATTCTCCTCGGCGGGCACGT

  • Gain-of-Function Smashing Success: The Key Sequence Inserted in the SARS-CoV-2 Virus Added at Least *FOUR* Distinct Functions. Coincidence?5)

SEB Insert

Researchers found that that a monoclonal antibody against SEB inhibits SARS-CoV-2 entry in vitro.6) It is interesting to note that the preprint of this paper was uploaded on November 24, 2020, but went unpublished for more than 9 months.

Data Controversies

1)
January 22, 2020 | Wei Ji et al | Journal of Medical Virology | Cross-species transmission of the newly identified coronavirus 2019-nCoV | https://doi.org/10.1002/jmv.25682
2)
December 17, 2021 | Ezequiel Mogro et al | preprint | Analysis of SARS-CoV-2 synonymous codon usage evolution throughout the COVID-19 pandemic | https://doi.org/10.1101/2021.12.17.472912
6)
September 2, 2021 | Mary Hongying Cheng et al | Structure (journal) | A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro | doi: 10.1016/j.str.2021.04.005
Back to top